#USA #New York #Medtronic #Pulnovo Medical #cardiac therapies

Pulnovo Medical Secures Strategic Investment from Medtronic

Pulnovo Medical, a leading company in innovative therapies for pulmonary hypertension and heart failure, has announced a successful funding round that raised an impressive $100 million. The strategic investment was spearheaded by Medtronic, one of the world's leading medical technology firms. This funding not only brings significant financial support but also boosts Pulnovo's capacity to enhance its groundbreaking medical solutions.

Breakthrough Investment Highlights

The funding round saw the participation of existing investors such as EQT, Qiming Venture Partners, Gaorong Ventures, OrbiMed, and Lilly Asia Ventures. Furthermore, new investors, including HSG (formerly known as Sequoia China) and other notable global entities, joined this endeavor. This infusion of capital marks a critical milestone for Pulnovo Medical, reflecting robust support from top-tier institutional and strategic investors. Their commitment underscores the potential of the company's technology and long-term vision for treating heart conditions.

Cynthia Chen, the CEO of Pulnovo Medical, emphasized the significance of integrating sector expertise and long-term capital to build a scalable growth model based on self-driven innovation. She stated, "This funding marks a crucial transition from a product-focused stage to a fully integrated global platform. As we continue to strengthen our clinical and technological capabilities, we remain committed to delivering meaningful innovations to patients worldwide."

Strategic Partnership with Medtronic

Alongside the investment, Pulnovo Medical and Medtronic have entered a commercial agreement aimed at leveraging potential future marketing opportunities. This partnership capitalizes on the inherent commercial synergies between the two companies, enhancing Pulnovo's capabilities with Medtronic's extensive global marketing prowess.

The patented Pulmonary Artery Denervation System (PADN) developed by Pulnovo addresses a key mechanism underlying cardiopulmonary diseases. Clinical results have shown significant improvements in patients’ functional capacity and outcomes. To date, Pulnovo has executed approximately 1,500 PADN procedures globally and obtained regulatory approvals in seven countries, with ongoing marketing expansion efforts in regions such as Europe, the Middle East, and China.

In the United States, Pulnovo has received FDA's Innovative Device designation and commenced two fully approved Investigational Device Exemption (IDE) trials, both led by Dr. Gregg Stone, a prominent figure in the field at Mount Sinai.

Use of Funds and Future Expansion

The proceeds from this financing are intended to support ongoing clinical development, global regulatory submissions, international marketing, and continued investment in the company's core technological platform. As part of its expansion strategy, Andre Xiao has been appointed as the Chief Strategy Officer, playing a pivotal role in strengthening Pulnovo's connection with global capital markets and industry ecosystems.

Xiao brings extensive experience from leading investment firms like Citadel and Millennium Management, where he specialized in global investments in medtech.

About Pulmonary Artery Denervation

Pulnovo's PADN system represents a pioneering, minimally invasive therapy designed to modulate the overactivity of the sympathetic nervous system that contributes to pulmonary vascular remodeling and progression of cardiopulmonary disease. This system has demonstrated clinically significant results in global studies, including improvements in functional capacity and reductions in adverse clinical events.

The therapy has been included in multiple international clinical guidelines, including the 2022 European Society of Cardiology (ESC) / European Respiratory Society (ERS) guidelines for diagnosing and treating pulmonary hypertension, and is referenced in a total of seven clinical guidelines to date.

Current clinical trials in various regions—especially in Europe and Asia—are nearing completion, and the recently started PULSE-LHD IDE trial in the U.S. will further reinforce clinical evidence surrounding PADN.

Conclusion

Pulnovo Medical remains dedicated to advancing innovative therapeutic solutions to address significant unmet medical needs in patients suffering from heart failure and related cardiopulmonary conditions. With substantial new funding and an enhanced strategic partnership with Medtronic, the company is poised for accelerated growth and transformative impacts in the healthcare landscape.